Cited by 272Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.

Therapeutic cancer vaccines: are we there yet?

Open access

Klebanoff, Christopher A., Acquavella, Nicolas, Yu, Zhiya, Restifo, Nicholas P.·2011·Immunological Reviews

DOI 10.1111/j.1600-065x.2010.00979.xPMC PMC3075547

Open this paper in CoChat — free account

Abstract

Summary: Enthusiasm for therapeutic cancer vaccines has been rejuvenated with the recent completion of several large, randomized phase III clinical trials that in some cases have reported an improvement in progression free or overall survival. However, an honest appraisal of their efficacy reveals modest clinical benefit and a frequent requirement for patients with relatively indolent cancers and minimal or no measurable disease. Experience with adoptive cell transfer‐based immunotherapies unequivocally establishes that T cells can mediate durable complete responses, even in the setting of advanced metastatic disease. Further, these findings reveal that the successful vaccines of the future must confront: (i) a corrupted tumor microenvironment containing regulatory T cells and aberrantly matured myeloid cells, (ii) a tumor‐specific T‐cell repertoire that is prone to immunologic exhaustion and senescence, and (iii) highly mutable tumor targets capable of antigen loss and immune evasion. Future progress may come from innovations in the development of selective preparative regimens that eliminate or neutralize suppressive cellular populations, more effective immunologic adjuvants, and further refinement of agents capable of antagonizing immune check‐point blockade pathways.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1600-065x.2010.00979.x

Cites

210 of 210 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846 · cited 8×
“These results contrast with the recent experience of combining the same gp100 peptide with bolus IL-2 where an increased fre- quency of objective responses and a significant improvement in progression free survival were observed compared with IL-2 administration alone (29).”
BackgroundInfluential
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
Petrylak, D. P., Tangen, C. M., Hussain, M., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D. L., Moinpour, C. M., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
Approaching the asymptote? Evolution and revolution in immunology.Preprint
Janeway, C. (1989) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1989.054.01.003 · Cited by 3,396
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Self-citation
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Self-citation
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
The FUTURE II Study Group (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061741 · Cited by 2,079
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043
Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children
Chang, M.-H., Chen, C.-J., Lai, M.-S., Hsu, H.-M., Wu, T.-C., Kong, M.-S., Liang, D.-C., Shau, W.-Y., & Chen, D.-S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706263362602 · Cited by 1,883
Effector and memory T-cell differentiation: implications for vaccine development
Kaech, S. M., Wherry, E. J., & Ahmed, R. (2002) · Nature Reviews Immunology · doi:10.1038/nri778 · Cited by 1,865 · cited 1×
“The paradigm for a prototypical naive T-cell response to an antigenic challenge, such as an acute viral infection, is that responding T cells undergo a multi-log clonal expansion, acquire effector functions and permeate peripheral tissues, clear the instigating pathogen, and subsequently contract to form a durable pop…”
Background
Lineage relationship and protective immunity of memory CD8 T cell subsets
Wherry, E. J., Teichgräber, V., Becker, T. C., Masopust, D., Kaech, S. M., Antia, R., von Andrian, U. H., & Ahmed, R. (2003) · Nature Immunology · doi:10.1038/ni889 · Cited by 1,864
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,786
Self-citation
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625
Self-citation
mTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575
Enhancing CD8 T-cell memory by modulating fatty acid metabolism
Pearce, E. L., Walsh, M. C., Cejas, P. J., Harms, G. M., Shen, H., Wang, L.-S., Jones, R. G., & Choi, Y. (2009) · Nature · doi:10.1038/nature08097 · Cited by 1,559
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421
Self-citation
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Dudley, M. E., Yang, J. C., Sherry, R. M., Hughes, M. S., Royal, R. E., Kammula, U. S., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,334
Self-citation
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
Paavonen, J. A., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S., Apter, D. L., Kitchener, H. C., Castellsagué, X., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60946-5 · Cited by 1,313
Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells
Kaech, S. M., & Ahmed, R. (2001) · Nature Immunology · doi:10.1038/87720 · Cited by 1,265
Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells
Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P. C., Celis, E., & Greenberg, P. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242600099 · Cited by 1,206
Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones
Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M., & Greenberg, P. D. (1992) · Science · doi:10.1126/science.1352912 · Cited by 1,202
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Pulè, M. A., Savoldo, B., Myers, G. D., Rössig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer
Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells
Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,073
Self-citation
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
Gattinoni, L., Zhong, X.-S., Palmer, D. C., Ji, Y., Hinrichs, C. S., Yu, Z., Wrzesinski, C., Boni, A., Cassard, L., Garvin, L. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1982 · Cited by 1,031
Self-citation
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Vaccine adjuvants: Current state and future trends
Petrovsky, N., & Aguilar, J. C. (2004) · Immunology and Cell Biology · doi:10.1111/j.0818-9641.2004.01272.x · Cited by 1,002
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glodé, L. M., Bilhartz, D. L., Wyand, M. S., Manson, K. H., Panicali, D., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 994
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells
Klebanoff, C. A., Gattinoni, L., Torabi‐Parizi, P., Kerstann, K. W., Cardones, A. R., Finkelstein, S. E., Palmer, D. C., Antony, P. A., Hwang, S. T., Rosenberg, S. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503726102 · Cited by 961
Self-citation
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 947
Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells
Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth‐Dreese, F. A., Dellemijn, T. A. M., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 926
Self-citation
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N. H., Wallen, H. D., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R. M., Jungbluth, A. A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 904
Towards an understanding of the adjuvant action of aluminium
Marrack, P., McKee, A. S., & Munks, M. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2510 · Cited by 887
Tumor-specific Th17-polarized cells eradicate large established melanoma
Muranski, P. J., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 864
Self-citation
Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation
van Stipdonk, M. J. B., Lemmens, E. E., & Schoenberger, S. P. (2001) · Nature Immunology · doi:10.1038/87730 · Cited by 843
Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer
Higano, C. S., Schellhammer, P. F., Small, E. J., Burch, P. A., Nemunaitis, J. J., Yuh, L., Provost, N. M., & Frohlich, M. W. (2009) · Cancer · doi:10.1002/cncr.24429 · Cited by 809
CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells
Antony, P. A., Piccirillo, C. A., Akpınarlı, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C., Chan, C., Klebanoff, C. A., Overwijk, W. W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2591 · Cited by 754
Self-citation
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697
Differentiation and persistence of memory CD8+ T cells depend on T cell factor 1
Zhou, X.-Y., Yu, S.-Y., Zhao, D.-M., Harty, J., Badovinac, V., & Xue, H.-H. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.002 · Cited by 689
Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A., Levine, E. G., Blumenstein, B. A., & Vogelzang, N. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.100 · Cited by 673
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.
North, R. J. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.4.1063 · Cited by 657
The mTOR Kinase Determines Effector versus Memory CD8+ T Cell Fate by Regulating the Expression of Transcription Factors T-bet and Eomesodermin
Rao, R. R., Li, Q., Odunsi, K., & Shrikant, P. A. (2010) · Immunity · doi:10.1016/j.immuni.2009.10.010 · Cited by 656
Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine
Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., & Rivoltini, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5829 · Cited by 646
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Vaccines: past, present and future
Plotkin, S. A. (2005) · Nature Medicine · doi:10.1038/nm1209 · Cited by 597
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 596
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials
Ault, K. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60852-6 · Cited by 589
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling
Paulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586 · cited 1×
“These include removal of antigen-irrelevant CD4 and CD8 T cells as well as NK cells which function as homeostatic cytokine sinks for the cytokines IL-7 and IL-15 (138, 140), a temporary depletion of suppressive cell populations such as CD4 CD25 FOXP3 T regulatory cells (Tregs) and MDSCs (133, 141), and mucosal injury…”
BackgroundSelf-citation
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells
Klebanoff, C. A., Finkelstein, S. E., Surman, D. R., Lichtman, M. K., Gattinoni, L., Theoret, M. R., Grewal, N. S., Spiess, P. J., Antony, P. A., Palmer, D. C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307298101 · Cited by 576
Self-citation
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Weber, J. S., Thompson, J. A., Hamid, O., Minor, D. R., Amin, A., Ron, I. G., Ridolfi, R., Assi, H. I., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 566
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
Parkhurst, M. R., Salgaller, M. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., & Kawakami, Y. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.6.2539 · Cited by 556
Targeting the innate immune response with improved vaccine adjuvants
Pashine, A., Valiante, N. M., & Ulmer, J. B. (2005) · Nature Medicine · doi:10.1038/nm1210 · Cited by 554
High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells
Serafini, P., Carbley, R., Noonan, K. A., Tan, G. G. Y., Bronte, V., & Borrello, I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0757 · Cited by 533
A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION
Teft, W. A., Kirchhof, M. G., & Madrenas, J. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090535 · Cited by 526
Improved Endpoints for Cancer Immunotherapy Trials
Hoos, A., Eggermont, A. M. M., Janetzki, S., Hodi, F. S., Ibrahim, R. A., Anderson, A., Humphrey, R. W., Blumenstein, B. A., Old, L. J., & Wolchok, J. D. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq310 · Cited by 517
CD8 + T‐cell memory in tumor immunology and immunotherapy
Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00391.x · Cited by 511
Self-citation
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
O'Day, S., Maio, M., Chiarion-Sileni, V., Gajewski, T., Pehamberger, H., Bondarenko, I., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq013 · Cited by 506
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
Klebanoff, C. A., Khong, H. T., Antony, P. A., Palmer, D. C., & Restifo, N. P. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.12.003 · Cited by 477
Self-citation
Early Programming of T Cell Populations Responding to Bacterial Infection
Mercado, R., Vijh, S., Allen, S. E., Kerksiek, K. M., Pilip, I. M., & Pamer, E. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.6833 · Cited by 477
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463
Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
Besser, M. J., Shapira‐Frommer, R., Treves, A. J., Zippel, D. B., Itzhaki, O., Hershkovitz, L., Levy, D., Kubi, A., Hovav, E., Chermoshniuk, N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0041 · Cited by 462
Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma
Rosenberg, S. A., Sherry, R. M., Morton, K. E., Sharfman, W., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U. S., Restifo, N. P., Hughes, M. S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6169 · Cited by 460
Self-citation
Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment
Koeneman, K. S., Yeung, F., & Chung, L. W. K. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990601)39:4 · Cited by 442
Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002
Horstmann, E., McCabe, M. S., Grochow, L. B., Yamamoto, S., Rubinstein, L., Budd, T., Shoemaker, D., Emanuel, E., & Grady, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa042220 · Cited by 441
High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma
Klapper, J. A., Downey, S. G., Smith, F. O., Yang, J. C., Hughes, M. S., Kammula, U. S., Sherry, R. M., Royal, R. E., Steinberg, S. M., & Rosenberg, S. A. (2008) · Cancer · doi:10.1002/cncr.23552 · Cited by 433
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer
Butts, C. A., Murray, N., Maksymiuk, A. W., Goss, G. D., Marshall, E., Soulières, D., Cormier, Y. F., Ellis, P., Price, A., Sawhney, R. P. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.011 · Cited by 427
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
Buyse, M. E., Thirion, P. G., Carlson, R. W., Burzykowski, T., Molenberghs, G., & Piedbois, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02528-9 · Cited by 425
Unopposed Production of Granulocyte-Macrophage Colony-Stimulating Factor by Tumors Inhibits CD8+ T Cell Responses by Dysregulating Antigen-Presenting Cell Maturation
Bronte, V., Chappell, D. B., Apolloni, E., Cabrelle, A., Wang, M. L., Hwu, P., & Restifo, N. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5728 · Cited by 404
Self-citation
Dynamic programming of CD8+ T lymphocyte responses
van Stipdonk, M. J. B., Hardenberg, G., Bijker, M. S., Lemmens, E. E., Droin, N. M., Green, D. R., & Schoenberger, S. P. (2003) · Nature Immunology · doi:10.1038/ni912 · Cited by 401
Host-reactive CD8+ memory stem cells in graft-versus-host disease
Zhang, Y., Joe, G., Hexner, E., Zhu, J., & Emerson, S. G. (2005) · Nature Medicine · doi:10.1038/nm1326 · Cited by 369
Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma
Dudley, M. E., Wunderlich, J. R., Nishimura, M. I., Yu, D. C., Yang, J. C.-H., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Sherry, R. M., et al. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200107000-00012 · Cited by 361
Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory
Jeannet, G., Boudousquié, C., Gardiol, N., Kang, J., Huelsken, J., & Held, W. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914127107 · Cited by 360
Prostate cancer as a model for tumour immunotherapy
Drake, C. G. (2010) · Nature reviews. Immunology · doi:10.1038/nri2817 · Cited by 351
Of Mice but Not Men
Hellmän, S., & Hellman, D. S. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242208 · Cited by 344
CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Dudley, M. E., Gross, C. A., Langhan, M. M., García, M. R., Sherry, R. M., Yang, J. C.-H., Phan, G. Q., Kammula, U. S., Hughes, M. S., Citrin, D. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1297 · Cited by 320
Self-citation
Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials
Roberts, T. G. (2004) · JAMA · doi:10.1001/jama.292.17.2130 · Cited by 319
T cell homeostatic proliferation elicits effective antitumor autoimmunity
Dummer, W., Niethammer, A. G., Baccalà, R., Lawson, B. R., Wagner, N., Reisfeld, R. A., & Theofilopoulos, A. N. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15175 · Cited by 316
Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas
Marshall, J. L., Gulley, J. L., Arlen, P. M., Beetham, P. K., Tsang, K.-Y., Slack, R. S., Hodge, J. W., DOREN, S., Grosenbach, D. W., Hwang, J. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.206 · Cited by 298
Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma
Mackensen, A., Meidenbauer, N., Vogl, S., Laumer, M., Berger, J., & Andreesen, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1100 · Cited by 297
Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells
Wrzesinski, C., Paulos, C. M., Kaiser, A., Muranski, P. J., Palmer, D. C., Gattinoni, L., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b88ffc · Cited by 284
Self-citation
A Clinical Development Paradigm for Cancer Vaccines and Related Biologics
Hoos, A., Parmiani, G., Hege, K. M., Sznol, M., Loibner, H., Eggermont, A. M. M., Urba, W. J., Blumenstein, B. A., Sacks, N., Keilholz, U., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211341.88835.ae · Cited by 270
T cell homeostatic proliferation elicits effective antitumor autoimmunity
Dummer, W., Niethammer, A. G., Baccalà, R., Lawson, B. R., Wagner, N., Reisfeld, R. A., & Theofilopoulos, A. N. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215175 · Cited by 267
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
Weide, B., Carralot, J.-P., Reese, A., Scheel, B., Eigentler, T. K., Hoerr, I., Rammensee, H.-G., Garbe, C., & Pascolo, S. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815ce501 · Cited by 261 · cited 1×
“(194) Melanoma Autologous tumor mRNA 8 0 Response rate 4 ⁄ 83 (4.”
Background
Adjuvants for cancer vaccines
Dubensky, T. W., & Reed, S. G. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.04.007 · Cited by 259
Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
Testori, A., Richards, J. M., Whitman, E. D., Mann, G. B., Lutzky, J., Camacho, L. H., Parmiani, G., Tosti, G., Kirkwood, J. M., Hoos, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9941 · Cited by 257
Structural Analysis of CTLA-4 Function In Vivo
Masteller, E. L., Chuang, E., Mullen, A. C., Reiner, S. L., & Thompson, C. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5319 · Cited by 252 · cited 1×
“Consequently, under limiting conditions, CTLA-4 may function as a B7 sink (101, 102).”
Background
Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
Smith, F. O., Downey, S. G., Klapper, J. A., Yang, J. C.-H., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Restifo, N. P., Levy, C. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0116 · Cited by 239
Self-citation
Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells can Induce Objective Clinical Responses and MART-1 Specific CD8+ T-cell Immunity
Palucka, A. K., Ueno, H., Connolly, J., Kerneis-Norvell, F., Blanck, J.-P., Johnston, D. A., Fay, J. W., & Banchereau, J. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211309.90621.8b · Cited by 234
A Phase I-II Study of α-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer
Motohashi, S., Nagato, K., Kunii, N., Yamamoto, H., Yamasaki, K., Okita, K., Hanaoka, H., Shimizu, N., Suzuki, M., Yoshino, I., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800126 · Cited by 231
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Weber, J. S. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0653-8 · Cited by 224
Phase III Study of Adjuvant Vaccination With Bec2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)
Giaccone, G., Debruyne, C., Felip, E., Chapman, P. B., Grant, S. C., Millward, M., Thiberville, L., DʼAddario, G., Coens, C., Rome, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.186 · Cited by 223
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
Kyte, J. A., Mu, L., Aamdal, S., Kvalheim, G., Dueland, S., Hauser, M., Gullestad, H. P., Ryder, T., Lislerud, K., Hammerstad, H., et al. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700961 · Cited by 219
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
Izumoto, S., Tsuboi, A., Oka, Y., Suzuki, T., Hashiba, T., Kagawa, N., Hashimoto, N., Maruno, M., Elisseeva, O. A., Shirakata, T., et al. (2008) · Journal of neurosurgery · doi:10.3171/jns/2008/108/5/0963 · Cited by 215
Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study
Berthold, D., Pond, G. R., Roessner, M., de Wit, R., Eisenberger, M. A., Tannock, A. I. F., & on behalf of the TAX-327 investigators (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0944 · Cited by 207
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
Pentcheva‐Hoang, T., Corse, E., & Allison, J. P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00763.x · Cited by 203
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells
Wrzesinski, C., Paulos, C. M., Gattinoni, L., Palmer, D. C., Kaiser, A., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30414 · Cited by 203
Self-citation
Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Amato, R. J., Hawkins, R. E., Kaufman, H. L., Thompson, J. A., Tomczak, P., Szczylik, C. A., McDonald, M., Eastty, S., Shingler, W. H., de Belin, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2082 · Cited by 199
Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer
Vinageras, E. N., de la Torre, A., Rodríguez, M. O., Ferrer, M. C., Cortada, I. B., del Pino, M. M., Abreu, D. A., Brooks, S. A., Rives, R., Carrillo, C. D. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5980 · Cited by 197
“MIATA”—Minimal Information about T Cell Assays
Janetzki, S., Britten, C. M., Kalos, M. D., Levitsky, H. I., Maecker, H. T., Melief, C. J. M., Old, L. J., Romero, P. J., Hoos, A., & Davis, M. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.007 · Cited by 192
Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Sznol, M., Schwarz, S. L., Spiess, P. J., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1690 · Cited by 185
Self-citation
Overall Survival: Still the Gold Standard
Driscoll, J. J., & Rixe, O. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181bdc2e0 · Cited by 183
Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer
Nemunaitis, J. J., Jahan, T. M., Ross, H. J., Sterman, D. H., Richards, D., Fox, B. A., Jablons, D. M., Aimi, J., Lin, A., & Hege, K. M. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700922 · Cited by 179
Constitutive Activation of Wnt Signaling Favors Generation of Memory CD8 T Cells
Zhao, D., Yu, S., Zhou, X., Haring, J. S., Held, W., Badovinac, V. P., Harty, J. T., & Xue, H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901199 · Cited by 176
Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy
Gattinoni, L., Ji, Y., & Restifo, N. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0356 · Cited by 176
Self-citation
Mannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma
Loveland, B. E., Zhao, A., White, S. C., Gan, H. K., Hamilton, K., Xing, P., Pietersz, G. A., Apostolopoulos, V., Vaughan, H. A., Karanikas, V., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1574 · Cited by 172
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
Slingluff, C. L., Petroni, G. R., Olson, W. C., Smolkin, M. E., Ross, M. I., Haas, N. B., Grosh, W. W., Boisvert, M. E., Kirkwood, J. M., & Chianese‐Bullock, K. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1544 · Cited by 171
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren, M., Arlen, P. M., Gulley, J. L., Rogatko, A., Cooper, H. S., Meropol, N. J., Alpaugh, R. K., Davey, M., McLaughlin, S. B., Beard, M., et al. (2001) · PubMed · Cited by 170
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial
Harrop, R., Connolly, N. B., Redchenko, I., Valle, J. W., Saunders, M. P., Ryan, M. G., Myers, K. A., Drury, N. L., Kingsman, S. M., Hawkins, R. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2732 · Cited by 166
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
Saenger, Y. M., & Wolchok, J. D. (2008) · PubMed Central · Cited by 164
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
El-Maraghi, R. H., & Eisenhauer, E. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5913 · Cited by 152
Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients
Nemunaitis, J., Nemunaitis, M., Senzer, N., Snitz, P., Bedell, C., Kumar, P., Pappen, B., Maples, P. B., Shawler, D., & Fakhrai, H. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.15 · Cited by 147
CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism
Engelhardt, J., Sullivan, T. J., & Allison, J. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1052 · Cited by 142
Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/− Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-α2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696
Kirkwood, J. M., Lee, S., Moschos, S. J., Albertini, M. R., Michalak, J. C., Sander, C., Whiteside, T. L., Butterfield, L. H., & Weiner, L. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1231 · Cited by 138
Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression
Madan, R. A., Gulley, J. L., Fojo, T., & Dahut, W. L. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0129 · Cited by 138
Vaccination with multiple peptides derived from novel cancer‐testis antigens can induce specific T‐cell responses and clinical responses in advanced esophageal cancer
Kono, K., Mizukami, Y., Daigo, Y., Takano, A., Masuda, K., Yoshida, K., Tsunoda, T., Kawaguchi, Y., Nakamura, Y., & Fujii, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01200.x · Cited by 135
The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses
Crawford, A., & Wherry, E. J. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.01.010 · Cited by 134
HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan
Kitano, S., Kageyama, S., Nagata, Y., Miyahara, Y., Hiasa, A., Naota, H., Okumura, S., Imai, H., Shiraishi, T., Masuya, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1546 · Cited by 132
Phase I Study of Immunization with Dendritic Cells Modified with Fowlpox Encoding Carcinoembryonic Antigen and Costimulatory Molecules
Morse, M. A., Clay, T. M., Hobeika, A. C., Osada, T., Khan, S., Hui, J. Y. C., Niedzwiecki, D., Panicali, D., Schlom, J., & Lyerly, H. K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2172 · Cited by 130
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity
Palmer, D. C., Chan, C., Gattinoni, L., Wrzesinski, C., Paulos, C. M., Hinrichs, C. S., Powell, D. J., Klebanoff, C. A., Finkelstein, S. E., Fariss, R. N., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710929105 · Cited by 130
Self-citation
New Therapies for Castration-Resistant Prostate Cancer
Longo, D. L. (2010) · New England Journal of Medicine · doi:10.1056/nejme1006300 · Cited by 128
Clinical Safety of a Viral Vector Based Prostate Cancer Vaccine Strategy
Arlen, P. M., Skarupa, L., Pazdur, M. P., Seetharam, M., Tsang, K. Y., Grosenbach, D. W., Feldman, J. L., Poole, D. J., Litzinger, M. T., Steinberg, S. M., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.05.117 · Cited by 124
Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma
Avigan, D., Vasir, B., George, D. J., Oh, W. K., Atkins, M. B., McDermott, D. F., Kantoff, P. W., Figlin, R. A., Vasconcelles, M. J., Xu, Y., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3180de4ce8 · Cited by 123
Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL
Goff, S. L., Smith, F. O., Klapper, J. A., Sherry, R. M., Wunderlich, J. R., Steinberg, S. M., White, D., Rosenberg, S. A., Dudley, M. E., & Yang, J. C.-H. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f05b91 · Cited by 123
Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma
Butterfield, L. H., Comin-Anduix, B., Vujanovic, L. N., Lee, Y., Dissette, V. B., Yang, J.-Q., Vu, H. T., Seja, E., Oseguera, D. K., Potter, D. M., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31816a8910 · Cited by 121
Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo
Lou, Y., Wang, G., Lizee, G. A., Kim, G. J., Finkelstein, S. E., Feng, C., Restifo, N. P., & Hwu, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1621 · Cited by 120
Self-citation
Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma
Nicholaou, T., Ebert, L. M., Davis, I. D., McArthur, G. A., Jackson, H. M., Dimopoulos, N., Tan, B. S., Maraskovsky, E., Miloradovic, L., Hopkins, W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2484 · Cited by 119
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.
Cheever, M. A., Greenberg, P. D., & Fefer, A. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.2.711 · Cited by 118
Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens
Slingluff, C. L., Petroni, G. R., Olson, W. C., Czarkowski, A. R., Grosh, W. W., Smolkin, M. E., Chianese‐Bullock, K. A., Neese, P. Y., Deacon, D. H., Nail, C. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3161 · Cited by 118
Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction
Palmer, D. C., Balasubramaniam, S., Hanada, K., Wrzesinski, C., Yu, Z., Farid, S. S., Theoret, M. R., Hwang, L. N., Klebanoff, C. A., Gattinoni, L., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7209 · Cited by 112
Self-citation
Vaccination of Patients With Advanced Non–Small-Cell Lung Cancer With an Optimized Cryptic Human Telomerase Reverse Transcriptase Peptide
Bolonaki, I., Kotsakis, A. P., Papadimitraki, E., Aggouraki, D., Konsolakis, G., Vagia, A., Christophyllakis, C., Nikoloudi, I., Magganas, E., Galanis, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3465 · Cited by 108
Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients
Fourcade, J. J., Kudela, P., Filho, P. A. A., Janjic, B. M., Land, S. R., Sander, C., Krieg, A. Μ., Donnenberg, A. D., Shen, H., Kirkwood, J. M., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318183af0b · Cited by 107
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
Svane, I. M., Pedersen, A. E., Johansen, J. S., Johnsen, H. E., Nielsen, D. L., Kamby, C., Ottesen, S., Balslev, E., Gaarsdal, E., Nikolajsen, K., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0293-4 · Cited by 104
Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma
Berntsen, A., Trepiakas, R., Wenandy, L., Geertsen, P. F., Straten, P. T., Andersen, M. H., Pedersen, A. E., Claësson, M. H., Lorentzen, T., Johansen, J. S., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181833818 · Cited by 103
Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer
Barve, M. A., BENDER, J. G., Senzer, N. N., Cunningham, C. C., Greco, F. A., McCune, D. E., Steis, R. G., Khong, H. T., Richards, D., Stephenson, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6462 · Cited by 100
Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma
Fakhrai, H., Mantil, J., Liu, L., Nicholson, G. L., Murphy-Satter, C. S., Ruppert, J. M., & Shawler, D. L. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700975 · Cited by 99
Cancer vaccines: progress reveals new complexities
Yu, Z., & Restifo, N. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16216 · Cited by 97
Self-citation
Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?
Ribas, A., Chmielowski, B., & Glaspy, J. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2376 · Cited by 95
Artificial Antigen-Presenting Cells for Use in Adoptive Immunotherapy
Turtle, C. J., & Riddell, S. R. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb33a6 · Cited by 94
Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval
Goffin, J. R., Baral, S., Tu, D., Nomikos, D., & Seymour, L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0130 · Cited by 91
A Phase I Trial of Vaccination of CA9-Derived Peptides for HLA-A24-Positive Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma
Uemura, H., Fujimoto, K., Tanaka, M., Yoshikawa, M., Hirao, Y., Uejima, S., Yoshikawa, K., & Itoh, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2253 · Cited by 91
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine
Faries, M. B., Hsueh, E. C., Ye, X., Hoban, M., & Morton, D. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1540 · Cited by 91
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
Rosenberg, S. A., Yang, J. C.-H., Schwartzentruber, D. J., Hwu, P., Topalian, S. L., Sherry, R. M., Restifo, N. P., Wunderlich, J. R., Seipp, C. A., Rogers-Freezer, L. J., et al. (2003) · PubMed · Cited by 90
Self-citation
Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells
Rapoport, A. P., Stadtmauer, E. A., Aqui, N. A., Vogl, D. T., Chew, A., Fang, H., Janofsky, S., Yager, K., Veloso, E. A., Zheng, Z., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0418 · Cited by 89
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer
Tsuruma, T., Iwayama, Y., Ohmura, T., Katsuramaki, T., Hata, F., Furuhata, T., Yamaguchi, K., Kimura, Y., Torigoe, T., TOYOTA, N., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-24 · Cited by 87
A Phase I/II Trial of a WT1 (Wilms' Tumor Gene) Peptide Vaccine in Patients with Solid Malignancy: Safety Assessment Based on the Phase I Data
Morita, S., Oka, Y., Tsuboi, A., Kawakami, M., Maruno, M., Izumoto, S., Osaki, T., Taguchi, T., Ueda, T., Myoui, A., et al. (2006) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyl005 · Cited by 87
Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results
Schuster, S. J., Neelapu, S. S., Gause, B. L., Muggia, F. M., Gockerman, J. P., Sotomayor, E. M., Winter, J. N., Flowers, C. R., Stergiou, A. M., & Kwak, L. W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2 · Cited by 85
Syngeneic Adoptive Immunotherapy and Chemoimmuno-therapy of a Friend Leukemia: Requirement for T cells
Berenson, J. R., Einstein, A. B., & Fefer, A. (1975) · The Journal of Immunology · doi:10.4049/jimmunol.115.1.234 · Cited by 83
Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors
Kaumaya, P. T. P., Foy, K. C., Garrett, J. T., Rawale, S. V., Vicari, D., Thurmond, J. M., Lamb, T., Mani, A., Kane, Y., Balint, C. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3883 · Cited by 83
A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
Schwartzentruber, D. J., Lawson, D. J., Richards, J. M., Conry, R. M., Miller, D. M., Triesman, J., Gailani, F., Riley, L., Vena, D. A., & Hwu, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra9011 · Cited by 83
Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV Melanoma
Weber, J. S., Boswell, W. D., Smith, J. W., Hersh, E. M., Snively, J., Diaz, M. I., Miles, S., Liu, X., Obrocea, M., Qiu, Z., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181611420 · Cited by 82
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the european lung cancer working party
Paesmans, M., Sculier, J., Libert, P., Bureau, G., Dabouis, G., Thiriaux, J., Michel, J., Cutsem, O. V., SERGYSELS, R., Mommen, P., et al. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00325-0 · Cited by 81
NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Gnjatic, S., Altorki, N. K., Tang, D. N., Tu, S., Kundra, V., Ritter, G., Old, L. J., Logothetis, C. J., & Sharma, P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2632 · Cited by 79
Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α)
Amato, R. J., Shingler, W. H., Goonewardena, M., de Belin, J., Naylor, S., Jac, J., Willis, J., Saxena, S., Hernandez-McClain, J., & Harrop, R. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ace876 · Cited by 78
A Phase I Study of Immunization Using Particle-Mediated Epidermal Delivery of Genes for gp100 and GM-CSF into Uninvolved Skin of Melanoma Patients
Cassaday, R. D., Sondel, P. M., King, D. M., Macklin, M. D., Gan, J., Warner, T. F., Zuleger, C., Bridges, A. J., Schalch, H., Kim, K. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2039 · Cited by 77
Novel Designs and End Points for Phase II Clinical Trials
Adjei, A. A., Christian, M. C., & Ivy, P. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2035 · Cited by 76
Experimental adenomas and carcinomas of the large intestine behave as distinct entities: Most carcinomas arisede novo in flat mucosa
Maskens, A. P., & Dujardin‐Loits, R. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1 · Cited by 75
Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells
Babatz, J., Röllig, C., Löbel, B., Folprecht, G., Haack, M., Günther, H., Köhne, C., Ehninger, G., Schmitz, M., & Bornhäuser, M. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0021-x · Cited by 70
Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer
Honma, I., Kitamura, H., Torigoe, T., Takahashi, A., Tanaka, T., Sato, E., Hirohashi, Y., Masumori, N., Tsukamoto, T., & Sato, N. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0691-x · Cited by 70
A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression
von Euw, E. M., Barrio, M. M., Furman, D., Levy, E. M., Bianchini, M., Péguillet, I., Lantz, O. J., Vellice, A., Kohan, A. I., Chacon, M. R., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-6 · Cited by 67
Immune Monitoring of T-Cell Responses in Cancer Vaccine Development
Keilholz, U., Martus, P., & Scheibenbogen, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2540 · Cited by 67
Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses
Koya, R. C., Mok, S., Comı́n-Anduix, B., Chodon, T., Radu, C. G., Nishimura, M. I., Witte, O. N., & Ribas, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008300107 · Cited by 66
Immunologic and Clinical Effects of Injecting Mature Peptide-Loaded Dendritic Cells by Intralymphatic and Intranodal Routes in Metastatic Melanoma Patients
Lesimple, T., Neidhard, E.-M., Vignard, V., Lefeuvre, C. P., Adamski, H., Labarrière, N., Carsin, A., Monnier, D., Collet, B., Clapisson, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1879 · Cited by 64
Pharmacologic Induction of CD8 + T Cell Memory: Better Living Through Chemistry
Gattinoni, L., Klebanoff, C. A., & Restifo, N. P. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000302 · Cited by 61
Self-citation
Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
Ohno, S., Kyo, S., Myojo, S., Dohi, S., Ishizaki, J., Miyamoto, K., Morita, S., Sakamoto, J., Enomoto, T., Kimura, T., et al. (2009) · PubMed · Cited by 59
Immunization of HLA-A*0201 and/or HLA-DPβ1*04 Patients with Metastatic Melanoma Using Epitopes from the NY-ESO-1 Antigen
Khong, H. T., Yang, J. C.-H., Topalian, S. L., Sherry, R. M., Mavroukakis, S. A., White, D. E., & Rosenberg, S. A. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00007 · Cited by 55
A Phase I Study of the Optimized Cryptic Peptide TERT572Y in Patients with Advanced Malignancies
Mavroudis, D., Bolonakis, I., Cornet, S., Myllaki, G., Kanellou, P., Kotsakis, A. P., Galanis, A., Nikoloudi, I., Spyropoulou, M., Menez, J., et al. (2006) · Oncology · doi:10.1159/000096252 · Cited by 55
The In vivo Expansion Rate of Properly Stimulated Transferred CD8+ T Cells Exceeds That of an Aggressively Growing Mouse Tumor
Hwang, L. N., Yu, Z., Palmer, D. C., & Restifo, N. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1679 · Cited by 53
Self-citation
Dendritic cell immunotherapy for stage IV melanoma
OʼRourke, M. G. E., Johnson, M. K., Lanagan, C. M., See, J. L., O’Connor, L., Slater, G. J., Thomas, D. M., López, J. A., Martinez, N. R., Ellem, K. A. O., et al. (2007) · Melanoma Research · doi:10.1097/cmr.0b013e3282c3a73b · Cited by 51
A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
Schwartzentruber, D. J., Lawson, D. J., Richards, J., Conry, R. M., Miller, D., Triesman, J., Gailani, F., Riley, L. B., Vena, D. A., & Hwu, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.cra9011 · Cited by 51
Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma
Lindsey, K. R., Gritz, L. R., Sherry, R. M., Abati, A. D., Fetsch, P. A., Goldfeder, L. C., Gonzales, M. I., Zinnack, K., Rogers-Freezer, L. J., Haworth, L. R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2061 · Cited by 50
Self-citation
Immune response to vaccination with DNA-hsp65 in a phase I clinical trial with head and neck cancer patients
Victora, G. D., Socorro-Silva, A., Volsi, E. C., Abdallah, K., Lima, F. D., Smith, R. B., Moysés, R. A., Zárate-Bladés, C. R., Michaluart, P., Silva, C. L., et al. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.9 · Cited by 49
Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma
Powell, A., Creaney, J., Broomfield, S., van Bruggen, I., & Robinson, B. W. S. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.01.007 · Cited by 49
Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432
Aoki, M., Ueda, S., Nishikawa, H., Kitano, S., Hirayama, M., Ikeda, H., Toyoda, H., Tanaka, K., Kanai, M., Takabayashi, A., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.018 · Cited by 49
Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma
Bachleitner‐Hofmann, T. (2009) · Oncology Reports · doi:10.3892/or_00000391 · Cited by 47
Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy
Okaji, Y., Tsuno, N. H., Tanaka, M., Yoneyama, S., Matsuhashi, M., Kitayama, J., Saito, S., Nagura, Y., Tsuchiya, T., Yamada, J., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.10.018 · Cited by 44
Landmark approval for Dendreon's cancer vaccine
DeFrancesco, L. (2010) · Nature Biotechnology · doi:10.1038/nbt0610-531 · Cited by 44
Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice
Lin, G. H. Y., Liu, Y., Ambagala, T., Kwon, B. S., Ohashi, P. S., & Watts, T. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011003 · Cited by 43
TCR Gene Therapy of Spontaneous Prostate Carcinoma Requires In Vivo T Cell Activation
de Witte, M. A., Bendle, G. M., van den Boom, M. D., Coccoris, M., Schell, T. D., Tevethia, S. S., van Tinteren, H., Mesman, E. M., Song, J., & Schumacher, T. N. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2563 · Cited by 41
Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results
Schuster, S. J., Neelapu, S. S., Gause, B. L., Muggia, F. M., Gockerman, J. P., Sotomayor, E. M., Winter, J. N., Flowers, C. R., Stergiou, A. M., & Kwak, L. W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.2 · Cited by 39
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: Results of a phase Ib/IIa study
Osorio, M., Gracia, E., Rodríguez, E., Saurez, G., Arango, M. D. C., Noris, E., Torriella, A., Joan, A., Gómez, E., Anasagasti, L., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.4.5476 · Cited by 38
Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma
Celis, E. (2007) · Cancer · doi:10.1002/cncr.22744 · Cited by 38
Spontaneous regression of metastases from malignant melanoma: a case report
Kalialis, L. V., Drzewiecki, K. T., Mohammadi, M., Mehlsen, A.-B., & Klyver, H. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e328307ee4c · Cited by 37
Phase I trial of personalized peptide vaccination for cytokine‐refractory metastatic renal cell carcinoma patients
Suekane, S., Nishitani, M., Noguchi, M., Komohara, Y., Kokubu, T., Naitoh, M., Honma, S., Yamada, A., Itoh, K., Matsuoka, K., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00631.x · Cited by 36
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes
Ugel, S., Scarselli, E., Iezzi, M., Mennuni, C., Pannellini, T., Calvaruso, F., Cipriani, B., Palma, R. D., Ricci‐Vitiani, L., Peranzoni, E., et al. (2009) · Blood · doi:10.1182/blood-2009-07-233270 · Cited by 33

Research works printed but not linked: 5

10.1172/JCI0216216 · DOI
Overwijk W, 2009, Peptide/incomplete freund adjuvant emulsion depots are a graveyard for tumor antigen‐specific CD8(+) T cells, J Immunother, 32, 971
Radvanyi L, 2008, Adoptive T‐cell therapy at the MD Anderson Cancer Center: early results and a promising future, J Immunother, 31, 924
Higano C, 2009, A Phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration‐resistant prostate cancer (CRPC), American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium (2009)
Small E, 2009, A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration‐resistant prostate cancer (CRPC), American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium (2009)

Sorted by citations

Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,545
Self-citation
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Self-citation
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,088
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
The Basis of Oncoimmunology
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843

See all 272

Authors: Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P.
Affiliations: National Institutes of Health (US)
Corresponding author: Restifo, Nicholas P.
ORCID: Klebanoff, Christopher A.
Yu, Zhiya
Restifo, Nicholas P.
Venue: Immunological Reviews
Publisher: Wiley
Published: 2010-12-28
Volume: 239
Issue: 1
Pages: 27-44
ISSN: 0105-2896 (ISSN-L)
1600-065X
DOI: 10.1111/j.1600-065x.2010.00979.x
PMC: PMC3075547
OpenAlex: W2132361489
Cited by: 271
References: 210
Citations by year: 2026: 2 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 12 · 2021: 11 · 2020: 12 · 2019: 19 · 2018: 14 · 2017: 16 · 2016: 21 · 2015: 36 · 2014: 22 · 2013: 33 · 2012: 34
FWCI: 2.24
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Immunological Reviews (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (ZIABC010763, ZIABC011037)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: therapeutic cancer vaccines, adoptive cell transfer, tumor microenvironment, regulatory T cells, myeloid cells, T cell exhaustion, tumor antigen loss, immune evasion, immunoadjuvant, immune checkpoint blockade, metastatic cancer, clinical trial efficacy
MeSH terms: Adjuvants, Immunologic, Antigens, Differentiation, T-Lymphocyte, Antigens, Neoplasm, Humans, Immunotherapy, Neoplasms, Randomized Controlled Trials as Topic, T-Lymphocyte Subsets, Treatment Outcome, Adoptive Transfer, Cancer Vaccines, Toll-Like Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic cancer vaccines: are we there yet?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks